enGene welcomes Paul Hastings and Wouter Joustra to its Board of Directors

– USA, MA / CANADA, Montreal –  enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), announced the election of Paul Hastings and Wouter Joustra to its Board of Directors at the 2024 AGM.

About Paul Hastings

Paul Hastings has served as the President, CEO, and a member of the board of directors of Nkarta, Inc. (NASDAQ: NKTX) since February 2018. Before that, he served as President, CEO, and Director of the publicly traded, clinical-stage biopharmaceutical company OncoMed Pharmaceuticals, Inc. from January 2006 until January 2018. In August 2013, he was elected Chairman of the board of directors of OncoMed and served in that role until January 2018. Before joining OncoMed, Mr. Hastings was President, CEO, and Director of QLT, Inc., a publicly traded biotechnology company dedicated to the development and commercialization of innovative ocular products, from February 2002 to September 2006. From 2000 to 2002, Mr. Hastings served as President, CEO, and Director of Axys Pharmaceuticals, Inc., which was acquired by Celera Corporation in 2001. Mr. Hastings was also previously the President of Chiron Biopharmaceuticals, a division of Chiron Corporation, President and CEO of LXR Biotechnology, and he held a variety of management positions of increasing responsibility at Genzyme Corporation, including President of Genzyme Therapeutics Europe and President of Worldwide Therapeutics.

Paul Hastings previously served on the board of directors of Relypsa, a publicly traded biotechnology company acquired by Galencia AG, as Chairman of the board of directors of Proteolix, Inc., a privately held biopharmaceutical company acquired by Onyx Pharmaceuticals, Inc., on the board of directors of ViaCell, Inc., a publicly traded biotechnology company sold to Perkin Elmer, and as a director of ViaCyte, Inc., a privately held regenerative medicine company acquired by Vertex Pharmaceuticals, Inc. Mr. Hastings currently serves as Chair of the board of Pacira Biosciences, Inc. (NASDAQ: PCRX), a biotechnology company, and the immediate past Chair and Board Executive Committee member of the Biotechnology Innovation Organization (BIO).

Paul Hastings received a B.S. in pharmacy from the University of Rhode Island.

About Wouter Joustra

Wouter Joustra is a General Partner at Forbion, a leading European life sciences venture capital firm. At Forbion, he is responsible for deal origination, general portfolio management, and divestment strategies, and focuses on Forbion’s Growth Opportunities Funds, which concentrates on investing in late-stage life sciences companies. Before joining Forbion in 2019, Mr. Joustra previously was a Senior Trader, as well as an Executive Board member of the Life Sciences franchise at Kempen, a European boutique investment bank. In this role, he managed Kempen’s trading portfolio and was involved in deal structuring and equity capital markets transactions, as well as larger block trades.

Wouter Joustra also served as a member of the board of directors of Gyroscope Therapeutics until the closing of its acquisition by Novartis in February 2022 for up to $1.5 billion, the board of directors of VectivBio (NASDAQ: VECT) from December 2022 until the closing of its $1.2 billion acquisition by Ironwood Pharmaceuticals in December 2023, the board of directors of Aiolos Bio until the closing of its acquisition by GSK plc in February 2024 for up to $1.4 billion and the board of Forbion European Acquisition Corporation, a special purpose acquisition company, until its completion of the business combination with enGene in October 2023.

Wouter Joustra serves on the board of directors of VectorY Therapeutics and holds a position as a board observer at New Amsterdam Pharma N.V. (NASDAQ: NAMS).

Wouter Joustra holds an M.Sc. in Business Administration from the University of Groningen, and a B.Sc. in International Business and Management from this same university.

About enGene

enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. enGene’s lead program is EG-70 for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG) – a disease with a high clinical burden. EG-70 is being evaluated in an ongoing Phase 2 pivotal study. EG-70 was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

SOURCE: enGene.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.